期刊文献+

老年患者急性高容量血液稀释配合控制性降压的可行性研究

A Study of the Feasibility of Acute Hypervolemic Hemodilution Combined with Controlled Hypotension Hypotension in the Elderly Patients
下载PDF
导出
摘要 目的评价围术期急性高容量血液稀释(AHH)配合控制性降压(CH)应用于老年患者的可行性。方法40例ASAI~Ⅱ级的全髋置换术老年病人随机分为AHH联合CH组(Ⅰ)和对照组(Ⅱ)各20例。术中监测MAP、CVP、HR、SPO2,分别在术前、AHH后1h和术后24h抽血测定Hb、Hct、Plt,记录术中出血量、输液量、输血量和尿量。结果Ⅰ组MAP显著低于术前(P<0.01)和Ⅱ组(P<0.01),两组CVP均明显升高(P<0.01),Ⅰ组低于Ⅱ组(P<0.01),两组HR无明显变化,Hb、Hct、Plt均显著下降(P<0.005~0.01),仍在正常范围内。Ⅰ组出血量明显少于Ⅱ组(P<0.05)。结论AHH联合CH可安全地应用于一般情况良好,无心肺疾患的老年患者,并有效的减少出血量。 Objective To evaluate the feasibility of acute hypervolemic hemodilution(AHH)combined with controlled hgpotension(CH)in the elderly patients during operation.Methods Forty ASA Ⅰ~Ⅱ elderly patients undergoing total-hip-replacement operation were randomized to AHH plus CH group(group Ⅰ)and control group(group Ⅱ),each group containing 20 patients.MAP,CVP,HR,and SPO2 were monitored during operation.Hb.Hct and Plt were also monitored before operation,1h after AHH and 24h after operation.The volume of blood loss,infusion,blood transfusion and urine were recorded during operation.Results MAP after operation in group Ⅰ was significantly lower than that before operation in groups Ⅰ and Ⅱ(P<0.01).CVP in the both groups obviously elevated,and CVP in the groupⅠwas significantly lower than that in groupⅡ(P<0.01),HR was comparable between the two groups.Hb,Hct and Plt significantly decreased after operation,but were still with normal range.The volume of blood loss in groupⅠwas less than that in groupⅡ(P<0.05).Conclusion AHH combined with CH can safely be applied to the elderly patients without cardiac and pulmonary disease,and effectively decreased the volume of blood loss.
出处 《中国实用医药》 2007年第9期1-3,共3页 China Practical Medicine
基金 广东省汕头市科技计划项目(2005116003)
关键词 血液稀释 降压 老年人 可行性研究 Hemodilution Controlled hgpotension Elderly patients Feasibility studies
  • 相关文献

参考文献4

二级参考文献15

  • 1王保国,郭小明.安氟醚或异氟醚控制性降压对血流动力影响的对比研究[J].中华麻醉学杂志,1993,13(3):186-189. 被引量:12
  • 2[1]Blumberg N, Joanna MH. Effects of transfusion on immunefunction function:Canncer recurrence and infection. Arch Pathol Lab Med,1994;118(4):371
  • 3[2]Alter HJ, Nakatsuji Y, Melpolder J,et al. The incidence of transfusion- associated hepatitis virus infection and its relation to liver disease. Nengl J Med, 1997;336(11):747
  • 4[3]Petz Ld. Platelet transfusion. In: Petz LD,Swisher SN,Kleinman S, ed. New York: Churchill Livingstone inc, 1996:367~380
  • 5[4]Goldsmith JC. The coagulation cascade and coagulation factorreplacement in hemophilia. In: Petz LD, Swisher SN, Kleinman S,et al. Clinical practice of transfusion medicine. 3rd ed. New York:Churchill Livingstone Inc, 1996:185~195
  • 6[5]Ciavarella D, Reed RL, Counts RB, et al. Clotting factorlevels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol, 1987; 67(2):365
  • 7[6]Furie B,Diuguid CF, Jacobs M, et al. Randomized prospective trial comparing the nativeprothrombin antigen with prothrombin tiom for monitoring oral anticoagulant therapy. Blood, 1990;75(2):344
  • 8[7]Iterson M van. Systemic haemodynamics and oxygenation during haemodilution in children. Lancet, 1995; 346:1127~1129
  • 9Mielke LL, Entholzner Ek, kling M, et al. Preoperative acute hypervolemic hemodilution with hydroxyethylstarch: an alternative to acute normovolemic hemodilution? [J].Anesth Analg, 1997,84:26- 30
  • 10Schreiber GB, Busch MP, Kleinman SH, et al. The Risk of Transfusion Transmitted Viral Infections[J]. N Engl J Med, 1996,334:1685 - 1690

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部